FDA orders clinical hold on Targeted Genetics trial

Share this article:
The FDA has ordered a clinical hold on a Targeted Genetics clinical trial involving tgAAC94, an investigational therapy indicated for treating inflammatory arthritis. The hold came after one subject experienced a serious adverse event, but the company says there is insufficient information to draw conclusions as to the cause.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.